Update on antifungal therapy with Terbinafine

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 3, 2010, Pages 415-424

  Gianni, C ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Dermatomycoses; Pulse therapy group; Terbinafine

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MONOAMINE OXIDASE B INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TERBINAFINE;

ABDOMINAL PAIN; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; AGRANULOCYTOSIS; CANDIDA ALBICANS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG TOLERABILITY; DYSPEPSIA; EPIDERMOPHYTON FLOCCOSUM; ERYTHEMA MULTIFORME; FIXED DRUG ERUPTION; HEADACHE; HUMAN; LIVER FAILURE; MALASSEZIA; MAXIMUM PLASMA CONCENTRATION; MEASLES LIKE RASH; NAUSEA; NEUTROPENIA; ONYCHOMYCOSIS; PANCYTOPENIA; PREVALENCE; RETINA DISEASE; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; THROMBOCYTOPENIA; TINEA CAPITIS; TINEA PEDIS; TOXIC EPIDERMAL NECROLYSIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; URTICARIA;

EID: 77956795042     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Stutz A. Synthesis and structure - activity correlations within allylamine antimycotics. Ann NY Acad Sci 1988;544:46-62.
2. Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol 1989;14:98-100.
3. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agent inhibiting fungal squalene epoxidase. Science 1984;224:1239-41. (Pubitemid 14109460)
4. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-84.
5. Schuster I. The interaction of representative members from two classes of antimycotics - the azoles and the allylamines - with cytochromes P-450. Xenobiotica 1985;15:529-46. (Pubitemid 15051911)
6. Shadomy S, Espinel-Ingroff A, Gebhart RJ. In vitro studies with SF 86-327, a new orally active allylamine derivative. J Med Vet Mycol 1985;23:125-32.
7. Richardson MD. Effect of Lamisil and Azole Antifungals in experimental nail infection. Dermatology 1997;194(Suppl 1):27-31.
8. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987;31:1365-8. (Pubitemid 17148303)
9. Clayton YM. In vitro activity of terbinafine. Clin Exp Dermatol 1989;14:101-3.
10. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994;130(Suppl 43):7-8.
11. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol 1998;38:S37-41.
12. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997;8:275-87. (Pubitemid 27527045)
13. Goudard M, Regli P, Buffard Y, Gabriel B. In vitro sensitivity of Aspergillus spp to terbinafine: comparative study on amphotericin B, 5-fluorocytosine and ketoconazolo. Pathol Biol 1988;36:139-43.
14. Alastruey-Izquierdo A, Cuesta I, Houbraken J, Cuenca-Estrella M, Manzon A, Rodriguez-Tudela JL. In vitro activity of nine antifungal agents clinical isolates of Aspergillus calidoustus. Med Mycol 2009;18:1-7.
15. Trovato L, Rapisarda MF, Greco AM, Galata F, Oliveri S. In vitro susceptibility of nondermatophyte moulds isolated from onychomycoses to antifungal drugs. J Chemother 2009;21:403-7.
16. Gupta AK, Sauder DN, Shear NH. Antifungal agents:an overview. Part II. J Am Acad Dermatol 1994;30:911-33.
17. Finlay AY, Lever L, Thomas R. Nail matrix kinetics of systemic terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990;1(Suppl):51-3. (Pubitemid 20348097)
18. Finlay AY. Pharmacokinetics of terbinafine. J Dermatol Treat 1992;3(Suppl 1):15-7.
19. Schatz F, Brautigam M, Dobrowolski E, Effendy I, Haberl H. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995;20:377-83.
20. .Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992;126(Suppl 39):28-32.
21. Faergemann J, Zehender H, Denouel J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol (Stockh) 1993;73:305-9.
22. Faergemann J, Zehender H, Jones T. Terbinafine levels in serum, stratum corneum, dermis-epidermidis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol 1991;71:322-6.
23. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-84.
24. Evans EGV. The clinical efficacy of terbinafine in the treatment of fungal infections of the skin. Rev Contemp Pharmacother 1997;8:325-41.
25. De Cuyper C. Long term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis. Br J Dermatol 1996;135:156-7. (Pubitemid 26225149)
26. Watson AB, Marley JE, Ellis DH, Williams TG. Terbinafine in onychomycosis of toenail: a novel treatment protocol. J Am Acad Dermatol 1995;33:775-9.
27. Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 1999;12:S6-9.
28. Charif MA, Elewski BE. Prevalence of onychomycosis in the United States: results of a population based survey (Abstr. 521). Presented at the 1996 Annual Meeting of the society for investigative dermatology. Washington, DC; 1996 May 1-5.
29. Ramani R, Srinivas CR, Ramani A, Kumari TG, Shivananda PG. Molds in onychomycosis. Int J Dermatol 1993;32:877-8.
30. Clayton YM. Clinical and mycological diagnostic aspects of onychomycosis and dermatomycoses. Clin Exp Dermatol 1992;17(Suppl 1):37-40.
31. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi. Mycoses 1989;32:609-19. (Pubitemid 20098285)
32. Williams HC. The epidemmiology of onychomycosis in Britain. Br J Dermatol 1993;129:101-9.
33. Onsberg P. Scopulariopsis brevicaulis in nails. Dermatologica 1980;161:259-64.
34. Degreef H. Onychomycosis. Br J Clin Pract 1990;44:91-7.
35. Lebwohl MG, Daniel R, Lyden J, Mormon M, Shavin J, Tschen E et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001;40:358-60.
36. Tosti A, Piraccini BM, Lorenzi S, Iorizzo M. Treatment of nondermatophyte mold and Candida onychomicosis. Dermatol Clin 2003;21:491-7. (Pubitemid 37022672)
37. Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp: 34 cases treated with weekly intermittent terbinafine. Dermatology 2004;209:104-10.
38. Zaias A. Management of onychomycosis with oral terbinafine. J Am Acad Dermatol 1990;23:810-2.
39. Goodfield MJD. Short duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre study. Br J Dermatol 1992;126(Suppl):33-5.
40. Goodfield MDJ. Short-duration therapy with terbinafine for dermatophyte onychomicosis: a multicentre trial. Br J Dermatol 1992;126(Suppl 39):33-5.
41. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomicosis with oral terbinafine. Clin Exp Dermatol 1989;14:120-3. (Pubitemid 19088555)
42. Brautigam M. Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. J Am Acad 1998;38:S53-6.
43. De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998;38:S57-63.
44. Havu V, Heikkila H, Kuokkanen K, Nuutinen M, Rantanen T, Saari S et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomicosis. Br J Dermatol 2000;142:97-102.
45. Hofmann H, Brautigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofuvin. Arch Dermatol 1995;131:919-22.
46. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? Arch Dermatol 1998;134:1551-4.
47. Goodfield MJD, Andrew L, Evans EGV. Short-term treatment of dermatophyte onychomycosis with terbinafine. Br J Dermatol 1992;304:1151-4.
48. De Backer M, De Keyser P, De Vroey C Lesafre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day -a double-blind comparative trial. Br J Dermatol 1996;134(Suppl. 46):16-7. (Pubitemid 26188447)
49. Van der Schroeff JG, Cirkel PKS, Cijns MB, Van Dijk TJA, Govaert FJ, Groeneweg DA et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992;126:36-9.
50. Schuster S, Munro CS. Single dose treatment of fungal nail disease. Lancet 1992;339:1066.
51. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approch. J Dermatol 1996;23:259-62.
52. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001;44:485-91.
53. Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol 2004;140:691-5.
54. Bootman JL. Cost-effectiveness of two new treatment for onychomycosis: an analysis of two comparative clinical trials. J Am Acad Dermatol 1998;38:S69-72.
55. Olafsson J, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol 2003;149(Suppl 64):15-8.
56. Kim HC, Jung KB, Shin DH et al. Comparison of compliance and cure rate of systemic antifungal therapy versus combination therapy with systemic and topical agent in toenail onychomycosis. Korean J Med Mycol 2002;7:35-41.
57. Hay RJ The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001;145(Suppl. 60):3-8. (Pubitemid 32990056)
58. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part II: Treatment rationale, including specific patient populations. J Dermatol Treat 2008;19:168-75.
59. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43:S70-S80.
60. Gupta AK and the Onychomycosis Combination Therapy Study Group, Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: A randomized, evaluator-blinded study. J Drugs Dermatol 2005;4:481-5.
61. Baran R, Feuilhade M, Combernale P, Datry A, Goettmann S, Pietrini P et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycosis affecting the nail region. Br J Dermatol 2000;142:1177-83.
62. Baran E, Bochenski J, Duczkowski M, et al. Combination therapy for onychomycosis with amorolfine nail lacquer and oral antifungal agents. Mikol Lek 2003;10:79-83.
63. Goodfield MJD, Evans EGV. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J Dermatol Treat 2000;11:259-62.
64. Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2009 [Epub ahead of print].
65. Nair AB, Kim HD, Davis SP, Etheredge R, Bareness M, Friden PM et al. An ex vivo toe model used to asses applicators for the ionophoretic ungual delivery of terbinafine. Pharm Res 2009;26:2194-201.
66. Barber K, Claveau J, Thomas R. Review of treatment for onychomycosis: consideration for special populations. J Cutan Med Surg 2006;10(Suppl.2):S48-53.
67. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part II: Treatment rationale, including specific patient populations. J Dermatolog Treat 2008;19:168-75. (Pubitemid 351883006)
68. Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol 2004;140:691-5.
69. Smith EB, Stein LF, Fivenson DP, Atillasoy ES. The safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomicosis of the feet. Int J Dermatol 2000;39:859-64.
70. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25.884 patients. Arch Dermatol 1997;133:1213-9. (Pubitemid 27443813)
71. Fard AS, Esmaelzadeh M, Larjani B. Assessment and treatment of diabetic foot ulcer. Int J Clin Pract 2007;61:1931-8.
72. Rich P. Onychomycosis and tinea pedis in patients with diabetics. J Am Acad Dermatol 2000;43:130-4.
73. Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW et al. Prevalence and epidemiology of toenail onychomicosis in diabetic subjects: a multicenter survey. Br J Dermatol 1998;139:665-71.
74. Gupta AK, Gover MD, Lynde CW. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomicosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 2006;20:1188-93.
75. Farkas B, Paul C, Dobozy A, Hunyadi J, Horvath A, Fekete G. Terbinafine (Lamisil) treatment of toenail onychomicosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicenter trial. Br J Dermatol 2002;146:254-60.
76. Cathcart S, Cantrell W, Elewski BE. Onychomicosis and diabetes. J Eur Acad Dermatol Venereol 2009;23:1119-22.
77. Williams TG, Hall M. Lack of interaction of oral terbinafine with oral contraceptives and healthy babies in a postmarketing surveillance study. Fifth Annual International Summit on Cutaneous Antifungal Therapy, Singapore; 1998. Abstract 67.
78. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of newtopical agents. J Am Acad Dermatol 1997;36:S3-S8. (Pubitemid 27078947)
79. Korting HC, Tietz HJ, Bräutigam M et al. One week terbinafine 1% cream (Lamisil) once daily is effective in thetreatment of interdigital tinea pedis: a vehicle controlled study. LAS-INT-06 Study Group. MedMycol 2001;39:335-40.
80. Korting HC, KienckeP, Nelles S, Rychlik R. Comparable efficacy and safety of various topical formulations of terbinafine in tinea pedis irrispective of the treatment regimen: results of a meta-analysis. Am J Clin Dermatol 2007;8:357-64. (Pubitemid 350176506)
81. Schafer-Korting M, Schoellmann C, Korting HC. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol Physiol 2008;21:203-10.
82. Kienzler JL, Queille-Russel C, Mugglestone C, Ortonne JP, Larnier C. Stratum corneum pharmacokinetics of the anti-fungal drug, terbinafine, in a novel topical formulation, for single-dose application in dermatophytoses. Curr Med Res Opin 2007;23:1293-302. (Pubitemid 46998439)
83. de Chauvin MF, Viguié-Vallanet C, Kienzler JL, Larnier C. Novel, single-dose, topical treatment of tinea pedis using terbinafine: results of a dose-finding clinical trial. Mycoses 2008;51:1-6.
84. Bergstresser PR, Elewski B, Hanifin J. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cure and relapse rates with 1 and 4 week treatment regimens. J Am Acad Dermatol 1993;28:648-51.
85. Ortonne JP, Korting HC, Viguié-Vallanet C, Larnier C, Savaluny E. Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete's foot): a randomized, double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2006;20:1307-13. (Pubitemid 44614633)
86. Hay RJ, Korting HC, Jones TC; on behalf of the Dermatology Expert Panel. Single-dose treatment of athlete's foot with terbinafine: report from a Dermatology Expert Panel. Expert Rev Dermatol 2007;2:133-8.
87. Gupta AK, Chow M, Daniel CR, Aly R. Treatments of tinea pedis. Dermatol Clin 2003;21:431-62.
88. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra and piedra. Dermatol Clin 2003;21:395-400.
89. Williams JV, Honig PJ, McGinley KJ, Leyden JJ. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatrics 1995;96:265-7.
90. Abdel-Rahman SM, Nahata MC, Powell DA. Response to initial griseofulvin therapy in pediatric patients with tinea capitis Ann Pharmacother 1997;31:406-10.
91. Nejjam F, Zagula M, Carbiac MD, Guessous M, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety, and pharmacokinetics. Br J Dermatol 1995;132:98-105.
92. Roberts BJ, Freidlander SF. Tinea capitis: a treatment update. Pediatr Ann 2005;34:191-200.
93. Lipozencic J, Skerlev M, Orofino-Costa R, Zaitz VC, Horvath A, Chouela E et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open label, high-dose griseofulvin in children with tinea capitis due to Microsporum spp. Br J Dermatol 2002;146:816-23.
94. Dragos V, Lunder M. Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children. Pediatr dermatol 1997;14:46-8. (Pubitemid 27102504)
95. Haroon TS, Hussain I, Aman S, Jahangir M, Kazmi AH, Sami AR. A randomized double-blind comparative study of terbinafine for 1,2 and 4 weeks in tinea capitis. Br J Dermatol 1996;135:86-8.
96. Chan Y, Freidlander SF. New treatments for tinea capitis. Curr Opin Infect Dis 2004;17:97-103.
97. Faergemann J, Jones TC, Hettler O, Loria Y. Pityrosporum ovale as the causative agent of seborrhoeic dermatitis: new treatment options. Br J Dermatol 1996;134(Supp 46):12-5. (Pubitemid 26188446)
98. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug treatment of dermatomycoses. Clin Exp Dermatol 1989;14:124-7.
99. Faergemann J, Hersle K, Nordin P. Pityriasis versicolor:clinical experience with Lamisil cream and Lamisil Derm Gel. Dermatology 1997;194(Suppl 1):19-21.
100. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997;36:788-92. (Pubitemid 27497339)
101. Cowley NC, Farr PM, Shuster S. The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol 1990;122:71-6.
102. Camera E, Cannistraci C, Brigand S, Colombo D, Picardo M. Scavenging effect of terbinafine on free radicals in vitro. Br J Dermatol 1999;140:640-4. (Pubitemid 29191381)
103. Cassano N, Amoruso A, Loconsole F, Vena GA. Oral terbinafine for the treatment of seborrhoeic dermatitis in adults. Int J Dermatol 2002;41:821-2.
104. Scaparro E, Quadri G, Virno G, Orifici C, Milani M. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001;144:854-7.
105. Francesconi G, Valle A, Passos S, Reis R, Galhardo M. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol 2009;11:1273-6.
106. Revankar SG, Nailor MD, Sobel JD. Use of Terbinafine in rare and refractory mycoses. Future Microbiol 2008;3:9-17.
107. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25 884 patients. Arch Dermatol 1997;133:1213-9. (Pubitemid 27443813)
108. McClellan KJ, Wiseman LR, Markham A. Terbinafine. An update of its use in superficial mycoses. Drug 1999;58:179-202.
109. Lamisil (terbinafine hydrochloride tablets) Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
110. Finlay AY. Pharmacokinetics of terbinafine. J Dermatol Treat 1992;3(Suppl 1):15-7.
111. Murphy M, Barnes L. Terbinafine induced lupus erythematosus. Br J Dermatol 1998;138:708-9.
112. Munn SE, Russell JRR. Terbinafine and fixed drug eruption. Br J Dermatol 1995;133:815-6.
113. Lamisil (terbinafine hydrochloride tablets) Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
114. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspect. Lupus 2009;18:935-40.
115. Doty RL, Haxel BR. Objective assessment of terbinafine-induced taste loss. Laringoscope 2005;115:2035-7.
116. Kovacs MJ, Alshammari S, Guenther L, Bourcier M. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994;31(Pt 1):806. (Pubitemid 24340757)
117. Gupta AK, Sonori GS, Del Rosso JQ, Bartos PB, Shear NH. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol 1998;38:765-7.
118. Barete S, Bissuel F, Longuet P, Pocidalo MA, Leport C, Vildè JL. Agranulocytosis au cours d'un traitement par terbinafine. Rev Med Interne 1997;18:258-9.
119. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25 884 patients. Arch Dermatol 1997;133:1213-9. (Pubitemid 27443813)
120. Lamisil (terbinafine hydrochloride tablets) Prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
121. Vickers AE, Sinclair JR, Zollinger M, Hietz F, Glanzel U, Johanson L et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for dru-drug interactions. Drug Metab Dispos 1999;27:1029-38.
122. Product information: Lamisil. Novartis [Internet]. [last accessed 2009 November; cited 2010 March 25). Available at: http://www.pharma.us.novartis.com/ products/name/lamisil.jsp
123. Abddel-Rahman SM, Gotschall RR, Kauffmann RE, Leeder JS, Kearns GL. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999;65:465-72.
124. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agent. Drug interactions of clinical significance. Drug Saf 1998;18:83-97.
125. Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit 2005;27:680-2. (Pubitemid 41437648)
126. Van Der Kuy PH, Van Den Heuvel HA, Kempen RW, Vanmolkot LM. Pharmacokinetic interaction between nortriptyline and terbinafine. Ann Pharmacother 2002;36:1712-4
127. Jensen P, Lehne G, Fauchald P, Simonsen S. Effect of oral terbinafine treatment on cyclosporin in pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol 1996;76:280-1. (Pubitemid 26246996)
128. Long CC, Hill SA, Thomas RC, Johnston A, Smith SG, Kendall F et al. Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. J Invest Dermatol 1994;102:740-3. (Pubitemid 24144254)
129. Gupta AK, Ross GS. Interaction between terbinafine and warfarin. Dermatology 1998;196:266-7.